m6620
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 10, 2018 (NCT03309150)
Timeline
Indications
Mechanism of action
- Serine-protein kinase ATMINHIBITOR
ATM inhibitor
- ATR/ATRIPINHIBITOR
ATR/ATRIP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05246111 | Phase 1 | Feb 15, 2022 | Merck KGaA |
| NCT04266912 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2020 | University of Texas at Houston |
| NCT03704467 | Phase 2 | Mar 4, 2019 | Merck KGaA, Merck Serono |
| NCT03718091 | Phase 2 | Jan 8, 2019 | Harvard University, Merck Serono |
| NCT03641547 | Phase 1 | Aug 31, 2018 | Merck KGaA, University of Oxford |
| NCT03309150 | Phase 1 | Jan 10, 2018 | Merck KGaA |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 4 | 2 | 2 | 2018 |
| Merck Serono | For profit | 2 | 1 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1